EN | RU
EN | RU

Help Support

Back

Trial evaluates high-dose vitamin C to treat critically ill COVID-19 patients

Trial evaluates high-dose vitamin C to treat critically ill COVID-19 patients Trial evaluates high-dose vitamin C to treat critically ill COVID-19 patients
Trial evaluates high-dose vitamin C to treat critically ill COVID-19 patients Trial evaluates high-dose vitamin C to treat critically ill COVID-19 patients

A pilot, multicenter, randomized controlled clinical trial was carried to explore whether high-dose vitamin C infusion was effective to treat severe coronavirus disease 2019 (COVID-19).

See All

Key take away

High-dose intravenous vitamin C appears to improve oxygenation in critically ill coronavirus-infected patients. However, it does not improve invasive mechanical ventilation-free days in 28 days (IMVFD28).

Background

A pilot, multicenter, randomized controlled clinical trial was carried to explore whether high-dose vitamin C infusion was effective to treat severe coronavirus disease 2019 (COVID-19).

Method

The study cohort included severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected subjects in the intensive care unit. Overall, 56 participants were randomly allocated to either: (i) High-dose intravenous vitamin C cohort (12 g vitamin C diluted in 50 ml of bacteriostatic water every 12 h at a rate of 12 ml/hour by infusion pump for seven days, n=27) or, (ii) Placebo cohort (50 ml of bacteriostatic water for injection in a similar manner within 48 hours of arrival to intensive care unit, n=29). IMVFD28 was the major endpoint while organ failure (Sequential Organ Failure Assessment [SOFA] score), 28-day mortality, and inflammation advancement (interleukin-6) were the secondary endpoints.

Result

No difference in IMVFD28 between the two groups was noted. The vitamin C group failed to lower the 28-day mortality, as shown in the following table:


During the seven-day therapy period, subjects in the vitamin C group had a constant increase in the PaO2/FiO2 (day 7: 229 vs. 151 mmHg), which was not noted in the control arm. Interleukin-6 in the vitamin C group was decreased compared to the placebo arm (19.42 vs. 158.00) on the 7th day.

Conclusion

High-dose intravenous vitamin C failed to improve IMVFD28. However, it may display a vital benefit in oxygenation for critically ill individuals with COVID-19, with an improvement in PaO2/FiO2

Source:

The Annals of Intensive Care

Article:

Pilot trial of high-dose vitamin C in critically ill COVID-19 patients

Authors:

Jing Zhang et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: